Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 2Oligodendroglioma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Multiple Myeloma 1Melanoma 1Liposarcoma, Myxoid 1Liposarcoma 1Glioma 1Ganglioneuroma 1Ganglioglioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1Advanced Solid Tumor 1

Interventions

toripalimab 2Trabectedin 2Doxorubicin 2Docetaxel 2Biopsy 2temsirolimus 1silmitasertib 1selinexor 1pazopanib 1palbociclib 1nilotinib 1mirdametinib 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1eribulin 1cemiplimab 1avelumab 1abemaciclib 1Vincristine 1Temozolomide 1Specimen Handling 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Proton Therapy 1Nelfinavir 1Irinotecan 1Immunoenzyme Techniques 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposarcoma × mirdametinib × Clear all
NCT06843967 2026-05-22

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
54 enrolled
Sarcoma

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡